Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.
Vertex Pharmaceuticals is making the largest acquisition in its history, beefing up its commercial portfolio with a $10 billion takeover of Crinetics Pharmaceuticals.
The Mon… [+3 chars]
The Mon… [+3 chars]